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Susceptibility to atherosclerosis is determined by both environmental and genetic factors. Its genetic determinants
have been studied by use of quantitative-trait–locus (QTL) analysis. So far, 21 atherosclerosis QTLs have been
identified in the mouse: 7 in a high-fat–diet model only, 9 in a sensitized model (apolipoprotein E– or LDL [low-
density lipoprotein] receptor–deficient mice) only, and 5 in both models, suggesting that different gene sets operate
in each model and that a subset operates in both. Among the 27 human atherosclerosis QTLs reported, 17 (63%)
are located in regions homologous (concordant) to mouse QTLs, suggesting that these mouse and human athero-
sclerosis QTLs have the same underlying genes. Therefore, genes regulating human atherosclerosis will be found
most efficiently by first finding their orthologs in concordant mouse QTLs. Novel mouse QTL genes will be found
most efficiently by using a combination of the following strategies: identifying QTLs in new crosses performed
with previously unused parental strains; inducing mutations in large-scale, high-throughput mutagenesis screens;
and using new genomic and bioinformatics tools. Once QTL genes are identified in mice, they can be tested in
human association studies for their relevance in human atherosclerotic disease.
Introduction
Atherosclerosis is the pathological basis of ischemic coro-
nary artery disease (CAD), the leading cause of death in
industrialized nations. It is characterized by accumula-
tion of plasma lipids, fibrous tissues, and cell components
(mostly macrophages, smooth-muscle cells, and lympho-
cytes) in large arteries. Atherosclerosis is a complex dis-
ease caused by both genetic (with ∼50% heritability) and
environmental (mostly diet) factors. The underlying genes
have been studied through genotype- and phenotype-
driven approaches. In the genotype-driven approach, a
gene suspected of contributing to atherosclerosis is tested
for a pathological role either in atherogenesis, by use of
transgenic/knockout animal models, or in rare Mendelian
forms of human atherosclerosis. Studies with mouse mod-
els have identified 180 atherosclerosis-regulating genes,
and some of their human orthologs have confirmed poly-
morphisms associated with human atherosclerotic dis-
eases, including genes encoding the angiotensin-convert-
ing enzyme (ACE [MIM 106180]); adrenergic receptor,
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beta 2 (ADRB2 [MIM 109690]); 5-lipoxygenase–acti-
vating protein (ALOX5AP [MIM 603700]); apolipopro-
tein E (APOE [MIM 107741]); coagulation factor VII
(F7 [MIM 227500]); fibrinogen, B beta polypeptide (FGB
[MIM 134830]); glycoprotein 1b, alpha polypeptide
(GP1BA [MIM 606672]); matrix metalloproteinase 3
(MMP3 [MIM 185250]); matrix metalloproteinase 9
(MMP9 [MIM 120361]); 5,10-methylenetetrahydrofolate
reductase (MTHFR [MIM 607093]); nitric oxide synthase
3, endothelial cell (NOS3 [MIM 163729]); serum para-
oxonase (PON1 [MIM 168820]); transforming growth
factor, beta 1 (TGFB1 [MIM 190180]); thrombospon-
din 2 (THBS2 [MIM 188061]); thrombospondin 4
(THBS4 [MIM 600715]); toll-like receptor 4 (TLR4
[MIM 603030]) (Agah and Topol 2002; Humphries and
Morgan 2004; Lusis et al. 2004; Manolio et al. 2004;
McCarthy et al. 2004); and tumor necrosis factor (ligand)
superfamily, member 4 (TNFSF4 [MIM 603594]) (Wang
et al. 2005b). In the phenotype-driven approach, no as-
sumption is made as to which genes cause a disease phe-
notype, and atherosclerosis is linked to chromosome lo-
cations, QTLs, in a genomewide scan. This approach has
the advantage of finding novel atherosclerosis-suscepti-
bility genes. Two reviews summarize some of these QTLs
(Allayee et al. 2003; Smith 2003).
Here, we present an updated review of atherosclero-
sis QTLs found in mice and humans, compare athero-
sclerosis QTLs found in the two most commonly used
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mouse models (diet-induced and sensitized), and com-
ment on their concordance with human atherosclerosis
QTLs. Finally, we propose future strategies for finding
novel genes regulating human atherosclerosis.
QTLs for Atherosclerotic Diseases in Humans
So far, nine genomewide scans have been reported for
human atherosclerotic diseases, including myocardial
infarction (MI), CAD, acute coronary syndrome (ACS;
acute MI and unstable angina), and carotid artery in-
timal-medial thickness (CIMT) (table 1). Thirty-one in-
dividual QTLs (those found in different populations, re-
gardless of whether they are at the same chromosomal
locations) have been identified. They are distributed on
27 chromosome locations, and four of them—on chro-
mosomes 2, 3, 12, and 13—are found in two popula-
tions, so there are 27 unique QTLs (fig. 1). Six genes
that have confirmed association with the risk of athero-
sclerotic diseases in at least two independent populations
lie in 6 of the 27 QTLs. Analyses consistently indicate
that ALOX5AP underlies the MI and stroke QTL on
proximal chromosome 13 (Ben-Asher and Lancet 2004;
Helgadottir et al. 2004; Lohmussaar et al. 2005). The
R353Q polymorphism in F7 is significantly associated
with MI (McCarthy et al. 2004), so it is a candidate for
the MI QTL on distal chromosome 13q. The C-1252T
polymorphism in the promoter region of MMP9 is as-
sociated with the size of complicated lesions and the
stenosis of coronary arteries (Zhang et al. 1999; Pollanen
et al. 2001), suggesting that it is the gene underlying the
ACS QTL on chromosome 20q. The C677T SNP in
MTHFR is significantly associated with CIMT in a Chi-
nese population and a Japanese population (Humphries
and Morgan 2004), making it a candidate for the top
chromosome 1p QTL. More than two dozen studies in-
dicate that the Q192R polymorphism of PON1 under-
lies the CAD QTL on chromosome 7q (Durrington et
al. 2001; Agah and Topol 2002), although a recent meta-
analysis revealed only a weak relative risk of 1.12 (95%
CI 1.07–1.16) (Wheeler et al. 2004). Association studies
in two groups of patients with MI revealed that a poly-
morphism in the first intron of TNFSF4 is associated
with the risk of MI and CAD, suggesting that it underlies
the CAD QTL on chromosome 1q (Wang et al. 2005b).
In addition, it is highly likely that MEF2A (encoding
myocyte enhancer factor 2A [MIM 600660]) is the gene
underlying the chromosome 15q MI QTL, because there
is a 7-aa deletion in MEF2A in all 13 of the patients
with MI but not from the 8 normal individuals from a
family (Wang et al. 2003a), and three novel mutations
in exon 7 of MEF2A are present in 4 of the 207 study
patients with CAD/MI but not in 191 control subjects
(Bhagavatula et al. 2004).
Of the 180 genes shown to influence atherosclerosis
in either gene-knockout or transgenic mouse models—
and at least 17 genes having confirmed polymorphisms
associated with human atherosclerotic diseases—only
about a quarter of them fall within human atheroscle-
rosis QTLs, as indicated in fig. 1. Half of the human
atherosclerosis QTLs have no obvious candidate genes,
which suggests that their genetic determinants are
unknown.
QTLs for Atherosclerosis in Mice
Atherosclerosis QTLs in mice have been identified in two
models: (1) a high-fat–diet model, in which a diet con-
taining 15% fat, 1.25% cholesterol, and 0.5% cholic
acid is used to induce atherosclerosis, and (2) the sen-
sitized model, in which mice deficient in Apoe—or low-
density lipoprotein receptor (Ldlr)—are used (Jawien et
al. 2004; Meir and Leitersdorf 2004). Apoe-deficient
mice develop atherosclerosis spontaneously when fed a
chow diet; their lesions develop faster when they are fed
a Western diet (containing 21% fat and 0.15% choles-
terol) and more so when they are fed the high-fat diet
described above. Ldlr-deficient mice also develop athero-
sclerotic lesions when fed the chow diet, but the lesions
are very small and take considerable time to develop;
feeding these mice a Western diet or the high-fat diet
described above accelerates their lesion formation.
A total of 15 studies using mouse models of athero-
sclerosis detected 35 individual QTLs. Among them,
there are 21 unique QTLs (QTLs identified in different
crosses but at the same chromosomal location are
counted as one unique QTL because they may have the
same underlying gene [table 2 and fig. 2]). Of the 21
QTLs, 7 are revealed only in the high-fat–diet model,
9 only in the sensitized model, and 5 in both models
(fig. 3). Of the 21 QTLs, 12 are replicated in more than
one cross, which enables the use of haplotype analysis
to narrow these QTLs (Wang and Paigen 2005b). The
causal genes underlying 2 of the 21 mouse atheroscle-
rosis QTLs have been identified: Tnfsf4 (Ox40l) for Ath1
(atherosclerosis susceptibility 1) on chromosome 1 (Wang
et al. 2005b) and Alox5 for Artles on chromosome 6
(Mehrabian et al. 2002). Additionally, Angptl3 is prob-
ably one gene underlying a complex locus, Ath8, on
chromosome 4, which may contain more than one QTL
(Korstanje et al. 2004).
Concordance of Human and Mouse Atherosclerosis
QTLs
The term “concordance” refers to the fact that QTLs
for the same trait but from different species map to ho-
mologous genomic regions. It was first used to describe
hypertension QTLs that map to homologous regions in
rats, mice, and humans (Stoll et al. 2000; Sugiyama et
Figure 1 Chromosome map of human QTLs for atherosclerotic diseases. Chromosomes are drawn to scale, on the basis of the length of
each from the Ensembl Human Genome Browser. Each bar to the right of a chromosome represents a human atherosclerosis QTL from one
population (see table 1). The size of the QTL is determined either as a 1.5-LOD CI or as 10 Mb on either side of the peak marker when
the information on CI is unavailable. Candidate genes are listed to the left of the chromosomes. Human homologous regions of mouse QTLs
that fall within the human QTLs are represented by red stars.
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Figure 2 Chromosome map of mouse atherosclerosis QTLs. Each chromosome is represented by a vertical line (centromeres at the top).
Genetic distances (in cM) from the centromere are drawn to scale (scale shown at lower left of the figure. Chromosomes are drawn to scale,
on the basis of the estimated cM position of the most distally mapped locus on the Mouse Genome Informatics (MGI) Web site. Mouse
atherosclerosis QTLs are represented by the bars to the right of each chromosome (interacting QTLs are not shown). Each bar represents a
QTL from one cross (sharing the same parental strains, regardless of the breeding strategy) in the specified mouse model (see table 2). The size
of the QTL is determined either as a 95% CI or as 10 cM on either side of the LOD score peak when the information on CI is unavailable.
Candidate genes are listed to the left of the chromosomes. Mouse homologous regions of human QTLs that fall within mouse QTLs are
represented by red stars.
Wang et al.: Genetics of Atherosclerosis 7
Figure 3 Comparison of mouse atherosclerosis QTLs found in
high-fat and sensitized models (Apoe/ and Ldlr/ mice), shown in
different colors. The number of QTLs concordant with human QTLs
is also shown.
al. 2001). It has since been observed for kidney disease
(Korstanje and DiPetrillo 2004) and plasma levels of high-
density lipoprotein (HDL) (Wang and Paigen 2005a),
low-density lipoprotein, and triglycerides (Wang and
Paigen 2005b). For atherosclerosis, 13 (62%) of the 21
mouse QTLs are concordant with human QTLs, and 17
(63%) of the 27 human QTLs are concordant with
mouse QTLs (figs. 1 and 2), suggesting that more than
half of the mouse and human atherosclerosis QTLs have
the same underlying genes. Thus, identifying them in one
species should greatly facilitate identifying them in the
other.
Concordant QTLs are found for five (71%) of the
seven mouse atherosclerosis QTLs in the high-fat model,
six (67%) of the nine in a sensitized model, and two
(40%) of the five in both models (fig. 3). Altogether,
more than half of the QTLs found in each model have
concordant human QTLs, so it cannot be said that one
model is more relevant to human atherosclerotic disease
than the other. Three reasons may explain why some of
the human QTLs do not have concordant mouse QTLs.
First, not enough mouse crosses have been made. Sec-
ond, and perhaps more important, C57BL/6 (B6) mice
were used as the susceptible parental strain in 11 of the
13 crosses made so far to detect mouse atherosclerosis
QTLs. Use of different susceptible strains may detect
different QTLs that are concordant with human QTLs.
Third, the size of atherosclerotic lesions in mice (used
as the phenotype in all the QTL studies in mice so far)
only partially corresponds to the incidence of human
atherosclerotic diseases. In fact, the incidence of human
ACS is determined not only by lesion size but also, more
importantly, by plaque stability. Thus, future mouse
QTL studies that include plaque stability as a phenotype
may identify additional QTLs that are concordant with
human atherosclerosis QTLs.
Strategies for Finding Novel Genes Regulating Human
Atherosclerosis
Using the Mouse-to-Human Strategy
Finding QTL genes in mice is much more cost-effec-
tive, less time consuming, and less fraught with ethical
issues than is finding them first in humans, especially now
that many new genetic, genomic, and bioinformatics
tools for the mouse are available (discussed in the “In-
tegrating Traditional Genetic Approaches with New Ge-
netic, Genomic, and Bioinformatic Resources and Tools”
section). After a QTL gene is identified in the mouse, it
can be tested in human association studies for its role
in human diseases. The completion of the human Hap-
Map project will greatly simplify such studies by facili-
tating the selection of representative SNPs of a haplotype
block. In addition, dense SNPs throughout the human
genome have made possible whole-genome association
studies, whereby the candidacy of all the genes in human
diseases are systematically studied (Ozaki et al. 2002;
Carlson et al. 2004).
This mouse-to-human strategy has been successfully
used to identify POMC (encoding pro-opiomelano-
cortin-alpha [MIM 176830]) as a gene influencing obe-
sity (Krude et al. 1998; Hixson et al. 1999); CTLA4
(encoding cytotoxic T-lymphocyte-associated protein 4
[MIM 123890]) as a gene contributing to autoimmune
disorders, including Graves disease, autoimmune hypo-
thyroidism, and type 1 diabetes (Ueda et al. 2003); and
EN2 (encoding engrailed 2 [MIM 131310]) as a gene
for autism-spectrum disorder (Gharani et al. 2004). This
strategy has also been used to identify an atherosclerosis-
susceptibility gene in humans. Ath1 is a QTL on chro-
mosome 1 that makes B6 mice more susceptible to ath-
erosclerosis than C3H mice (Paigen et al. 1987a, 1987b).
By using congenic strains, we narrowed Ath1 to a 0.66-
cM region containing 11 genes (Phelan et al. 2002).
Three of the 11 genes could be involved in atheroscle-
rosis: Prdx6 (peroxiredoxin 6 [also called “antioxidant
protein 2”]) encodes an antioxidant (Steinberg and Witz-
tum 2002), Tnfsf4 encodes a membrane protein on lym-
phocytes and endothelial cells (Hansson et al. 2002), and
Fasl (Fas ligand) is important for apoptosis (Geng 2001).
After analyzing atherosclerosis susceptibility in mouse
mutants for each of these genes, we found that only
Tnfsf4-targeted mutants were significantly less suscep-
tible to diet-induced atherosclerosis than were wild-type
controls and that mice overexpressing Tnfsf4 were more
susceptible to atherosclerosis than were wild-type con-
trols. We then tested SNPs in TNFSF4 as well as in the
nearby genes in human association studies, and we
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found that only a polymorphism of TNFSF4 was sig-
nificantly associated with the risk of MI and CAD in
humans (Wang et al. 2005b). We therefore identified a
human atherosclerosis gene from a mouse QTL.
Making More Mouse Crosses
Although 21 mouse atherosclerosis QTLs have been
revealed, additional mouse crosses will expedite finding
genes that regulate atherosclerosis, for the following rea-
sons. First, among the 25 individual mouse atheroscle-
rosis QTLs published since 2003, 14 are new, and only
11 are replicates of QTLs found before, suggesting that
the mouse QTL map has not been saturated and that new
QTLs will be identified in new crosses. Second, addi-
tional mouse crosses may confirm previously found QTLs
(nearly half of the mouse QTLs are found in only one
cross) and may provide more strains for haplotype analy-
sis (Wang et al. 2004b; Wang and Paigen 2005b). Third,
11 of the 13 crosses use B6 as the susceptible parent. Using
different susceptible strains—such as SM/J, SWR/J, and
NON/LtJ—may reveal different QTLs. Fourth, there are
27 human and only 21 mouse QTLs, and 10 of the 27
human ones have no concordant mouse QTL. Addi-
tional mouse crosses may reveal QTLs concordant with
these human QTLs and may expedite finding their un-
derlying genes with the mouse-to-human strategy.
Including Plaque Stability and Coronary
Atherosclerosis as Phenotypes
Effective treatment of human atherosclerosis should
include stabilizing plaque as well as reducing the accu-
mulation of plasma lipids, and consequently the forma-
tion of fibrolipid cores in the arterial wall. So far, the
only atherosclerosis phenotype used in mouse genome-
wide-scan studies is the size of the lipid-staining lesions.
Thus, some of the genes identified may regulate intimal
lipid deposition but not plaque stability. The latter may
be more relevant to clinical events of human atheroscle-
rosis, because ACS is usually caused by plaque rupture
and the subsequently formed thrombi that obstruct coro-
nary arteries rather than increased plaque size. Thus,
future genomewide scans should include phenotypes that
reflect stability of atherosclerotic plaques, such as thick-
ness and rupture of fibrous cap and formation of in-
traplaque hemorrhage, thrombus, and buried fibrous
cap. Plaque rupture has been observed in B6 mice with
deficiency of Apoe when mice are fed either chow (Ro-
senfeld et al. 2000) or a diet with high-cholesterol con-
tent (Johnson and Jackson 2001; Williams et al. 2002;
Johnson et al. 2005). The most frequently observed site
of rupture is the innominate (brachiocephalic) artery, as
shown in the studies just cited, and genes controlling
atherosclerosis in the innominate artery and aortic root
may be different (Reardon et al. 2003; Teupser et al.
2004). The vessels most relevant to human atheroscle-
rotic diseases are, of course, the coronary arteries. Ad-
vanced atherosclerotic lesions do occur in mouse coro-
nary arteries when mice are deficient in either Apoe, Ldlr,
both Apoe and Ldlr, or Scarb1 (encoding scavenger re-
ceptor class B, member 1) and when they are fed either
chow (Braun et al. 2002) or a diet with high-cholesterol
content (Caligiuri et al. 1999; Calara et al. 2001). Thus,
future genomewide scans in mice perhaps should include
coronary atherosclerosis as a phenotype.
Finding Genes Regulating Human Atherosclerosis
by Studying QTLs for Both Atherosclerosis and HDL
So far, 37 mouse and 30 human HDL-regulating QTLs
have been identified (Wang and Paigen 2005a). Some of
the genes underlying these QTLs may also regulate ath-
erogenesis, given the compelling evidence that HDL pro-
tects against atherosclerosis (Brewer 2004; Gotto and
Brinton 2004). Thus, human atherosclerosis-regulating
genes can be identified by either (1) finding the gene
underlying a mouse atherosclerosis QTL and then testing
it for a role in human atherosclerosis or (2) finding the
gene underlying a mouse HDL QTL and then testing
whether it regulates HDL levels and atherosclerosis in
humans.
Integrating Traditional Genetic Approaches with New
Genetic, Genomic, and Bioinformatic Resources
and Tools
A QTL interval is usually large and typically contains
hundreds of genes. The first step toward finding a causal
gene is to narrow the QTL. QTL-narrowing strategies
that take advantage of recombinations in mouse crosses
include one or more of the following: (1) interval-specific
congenic strains, (2) advanced intercross lines, (3) het-
erogeneous stocks, (4) recombinant inbred (RI) segre-
gation test, (5) recombinant progeny testing, (6) selective
phenotyping, (7) yin-yang cross, and (8) collaborative
cross.
Interval-specific congenic strains.—Mice that are re-
combinant in the QTL region are crossed for several
generations with the background parental strain to elim-
inate alleles from the donor parental strain at all QTLs
affecting the trait (other than the QTL being mapped).
Animals are then intercrossed, and homozygotes for the
recombinant haplotype are selected to establish one con-
genic strain. Several congenic strains with overlapping
regions can differentiate which region contains the QTL
gene (Darvasi 1998). Recently, two sets of mice with
overlapping congenic regions, covering the whole ge-
nome, were generated; one set is B6.DBA/2, the other is
B6.CAST. These sets will facilitate narrowing QTLs from
B6# DBA/2 and B6# CAST crosses (Iakoubova et al.
2001).
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Advanced intercross lines.—Mice from two inbred pro-
genitor strains are crossed to yield F1 offspring, which
are intercrossed to produce F2 offspring. Fifty F2# F2
matings are made (avoiding brother-sister matings) to
produce F3 offspring, and fifty F3 # F3 matings are
made (avoiding brother-sister and cousin matings) to
produce F4 offspring, and so on, until the desired ad-
vanced intercross (F5, F6, and so on) is attained. Thus,
the many recombinations required to narrow a QTL
accumulate in a relatively small final population (Dar-
vasi 1998).
Heterogeneous stocks.—Heterogeneous stocks are de-
rived from multiple inbred strains (eight strains in cur-
rent stocks) through continued intercrossing. They are
essentially advanced intercross lines made from multiple
strains instead of two (Mott et al. 2000).
RI segregation test.—This strategy requires an existing
set of RI strains and takes advantage of the high mapping
resolution of RI strains and applies it to QTL mapping.
An RI strain with a recombinant haplotype in the region
of interest is crossed with both parental strains to pro-
duce two separate F1 populations. Intercrossing these F1
individuals then produces F2 mice. By analysis of the F2
populations, a QTL can be located relative to the re-
combination point, because the QTL previously mapped
to this region will segregate in only one of the two F2
populations (Darvasi 1998).
Recombinant progeny testing.—Mice carrying a recom-
binant chromosome in the QTL region are crossed with
one of the parental strains, and their progeny are pheno-
typed to determine the location of the QTL relative to
the recombination point (Darvasi 1998).
Selective phenotyping.—In a large intercross or back-
cross population, only individuals recombinant at an
interval previously found to contain a QTL are pheno-
typed, because only those individuals contribute to fur-
ther mapping accuracy (Darvasi 1998).
Yin-yang cross.—Yin-yang cross is a generalization of
the RI segregation test that uses inbred strains as if they
are RI lines (Shifman and Darvasi 2005). This method
is based on the observation that the many inbred lab-
oratory mice are derived from a limited number of foun-
der populations, so the large number of recombination
events accumulated in inbred strains since their origin
can be used to fine map a QTL to a very small region.
The statistical analysis of a yin-yang cross depends on
the knowledge of the SNPs of the strains used and is
actually similar to haplotype analysis of multiple crosses
(Hitzemann et al. 2002; Park et al. 2003; Manenti et al.
2004; Wang et al. 2004b).
Collaborative cross.—The collaborative cross is not an
existing resource, but it has been recently proposed
(Churchill et al. 2004). It is a panel of 1,000 RI strains
derived from eight inbred strains. With an estimated
135,000 unique recombination events and known geno-
types in the whole panel, QTLs can be mapped to a very
small interval without making any crosses.
However, all these approaches require many recom-
binant animals, which makes the analyses slow, labor
intensive, and sometimes difficult to generate because of
the existence of recombination hotspots (Kelmenson et
al. 2005). In addition to the above strategies, new genetic
and genomic resources, especially mouse and human ge-
nome sequences, have led to new strategies in narrowing
a QTL and even in identifying its underlying gene by
analysis of combined cross data, comparison of mouse
and human homologous QTLs, analysis of SNPs and
haplotypes in multiple strains, and detection of in silico
QTLs, as discussed by Wang and Paigen (2005b). It
should be cautioned that successfully identifying a QTL
gene from haplotype analysis and in silico QTL mapping
depends in large part on detailed genome sequence/SNP
information in many strains, which is only partly avail-
able now. A complete sequence of more mouse strains
is likely to fully empower haplotype analysis and in silico
QTL mapping, as reviewed by Flint et al. (2005). Once
a QTL is narrowed with the above approaches, candi-
date genes can be tested for sequence and expression
difference between parental strains (Wang and Paigen
2005b). To study the genetics of gene expression, Jansen
and Nap proposed a genomewide scan using gene-ex-
pression data as phenotypes that can be obtained from
microarray analysis (Jansen and Nap 2001); chromo-
some segments thus obtained are called “expression
QTLs” (eQTLs). Because the vast majority of eQTL genes
are cis-regulated (Bystrykh et al. 2005; Chesler et al.
2005; Hubner et al. 2005), candidate genes of a physio-
logical QTL (pQTL) (with use of clinical traits as phe-
notype) can be identified by overlapping such a pQTL
with eQTLs: differentially expressed genes in a pQTL
region could be good candidates (Schadt et al. 2003;
Chesler et al. 2005; Hubner et al. 2005).
Using Mutagenesis as a Complementary Approach
Although the QTL approach takes advantage of spon-
taneous mutations that had accumulated in the past and
had been fixed in the various inbred strains of laboratory
mice (Lander and Botstein 1989), a mutagenesis approach
is capable of generating, in a short time, large numbers
of mutations across the genome (Balling 2001). Very
efficient at low toxicity, ENU is an alkylating mutagen
that induces ∼ random point mutations per lo-31# 10
cus. It affects germ cells, particularly spermatogonial stem
cells. Once adult mice are mutagenized, they are bred,
and offspring abnormalities are detected in high-through-
put phenotyping screens. Deviants are tested for herit-
ability (Balling 2001). The large-scale and high-through-
put features of mutagenesis can potentially generate mu-
tations in every gene. Some of these mutations will help
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us understand a gene’s functions. The HLB Mutagenesis
Program at The Jackson Laboratory is using ENU mu-
tagenesis to identify genes regulating a wide range of
cardiovascular phenotypes (Svenson et al. 2003). Ath-
erosclerosis in mutagenized mice cannot be screened
with either cross-sectional (Paigen et al. 1987c) or en
face analysis (Palinski et al. 1994), because deviant mice
need to be kept for breeding. Instead, noninvasive meth-
ods should be used. Magnetic resonance imaging (MRI)
provides high-resolution images on not only lesion size
(Fayad et al. 1998; Choudhury et al. 2002; Hockings et
al. 2002) but also its components (lipid core and cap)
(McAteer et al. 2004; Schneider et al. 2004). MRI could
be used for an atherosclerosis screen in mutagenized
mice if the throughput could be increased.
Summary
The most efficient way to find atherosclerosis-regulating
genes in humans is to first find orthologs underlying con-
cordant QTLs, preferably replicate ones, in the mouse.
Such QTLs will increase in numbers as new mouse
crosses are performed, and they can be rapidly narrowed
by analysis of combined cross data, in silico QTL analy-
ses, and haplotype analyses. Because replicated QTLs
are likely caused by conserved ancestral alleles, causal
genes within the narrowed region should exhibit sequence
and/or expression differences consistent with their allele
effects in all parental strains. These candidate genes, if
associated with atherosclerotic diseases in humans, can
then be tested, positively identified, and their functions
studied in transgenic and/or knockout mice.
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